FIELD: chemistry.
SUBSTANCE: present invention relates to a compound of formula 
I or a pharmaceutically acceptable salt thereof, where R1 denotes C1-C8-alkylaminocarbonyl, which is optionally substituted with a 5- or 6-member heterocyclic ring containing 3-4 ring heteroatoms selected from a group consisting of oxygen, nitrogen and sulphur, where the ring can be optionally substituted with C1-C8-alkyl or C1-C8-alkoxy group ; R2 denotes C1-C3-alkyl or a halogen; one of R3 and R4 denotes R6, and the other denotes R7; R5 denotes hydrogen or halogen; R6 denotes hydrogen, hydroxy group amino group, -SO2R8, -SO2NH2, -SO2NR9R10, -COR8, -CONHR8, -NHSO2R8, nitrile, carboxy, -OR8 or C1-C8-halogenalkyl; R7 denotes hydrogen, OR11, halogen, carboxy, -SO2R8, cyanogroup or C1-C8-halogenalkyl, or when R4 denotes R7, then R7 can also denote -NR12 R13 ; R8 R11 independently denote C1-C8-alkyl or C3-C8-cycloalkyl, which can be optionally substituted with hydroxy group, C1-C8-alkoxy group, nitrile, amino group, C1-C8-alkylamino group or di-C1-C8-alkyl)amino group; any R9 denotes C1-C8-alkyl or C3-C8-cycloalkyl, which can optionally be substituted with hydroxy group, C1-C8-alkoxy group, nitrile, amino group, C1-C8-alkylamino group, di(C1-C8-alkyl)amino group or a 5- or 6-member heterocyclic ring containing one or two ring heteroatoms selected from a group consisting of oxygen and nitrogen, where the ring can optionally be substituted with C1-C8-alkyl, and R10 denotes hydrogen or C1-C8-alkyl; or R9 and R10 together with a nitrogen atom with which they are bonded form a 5- or 6-member heterocyclic ring which can contain one or two additional nitrogen heteroatoms, where the ring can be optionally substituted with C1-C8-alkyl; any R12 denotes C1-C8-alkyl or C3-C8-cycloalkyl which can be optionally substituted with di(C1-C8-alkyl)aminogroup, and R13 denotes hydrogen or C1-C8-alkyl; or R12 and R13 together with a nitrogen atom with which they are bonded form a 5- or 6-member heterocyclic ring which contains one or two additional nitrogen heteroatoms, where the ring can optionally be substituted with C1-C8-alkyl.
EFFECT: possibility of using the compounds to produce a pharmaceutical agent for treating diseases mediated by phosphatidylinositol-3 kinase.
6 cl, 3 tbl, 181 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 5-PHENYLTIAZOL DERIVATIVES AND THEIR APPLICATION IN CAPACITY OF P13 KINASE INHIBITORS | 2003 |
|
RU2378263C2 |
| PURINE DERIVATIVES FOR APPLICATION AS AGONISTS OF ADENOSINE RECEPTOR A-2A | 2005 |
|
RU2403253C2 |
| DERIVATIVES OF CYCLIC AMINES, METHOD FOR INHIBITION | 1998 |
|
RU2216540C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2668952C2 |
| INHIBITORS OF BACTERIAL GYRASE AND THEIR APPLYING | 2001 |
|
RU2262932C2 |
| PURINE DERIVATIVES AS A RECEPTOR AGONISTS | 2006 |
|
RU2400483C2 |
| QUINAZOLINE DERIVATIVES EXHIBITING TYROSINE KINASE INHIBITING ACTIVITY | 2006 |
|
RU2414457C2 |
| AMINOPIPERIDINE DERIVATIVES AS CETP INACTIVATORS (CHOLESTEROL ESTER TRANSFER PROTEIN) | 2007 |
|
RU2442782C2 |
| PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | 2007 |
|
RU2485115C2 |
| PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | 2004 |
|
RU2481346C2 |
